A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study-Reference-Cited by-同舟云学术

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

Published:2014-01-17 Issue:1 Volume:14 Page:
ISSN:1471-2466
Container-title:BMC Pulmonary Medicine
language:en
Short-container-title:BMC Pulm Med

Author:

Chapman Kenneth R,Beeh Kai-Michael,Beier Jutta,Bateman Eric D,D’Urzo Anthony,Nutbrown Robert,Henley Michelle,Chen Hungta,Overend Tim,D’Andrea Peter

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine

Link

http://link.springer.com/article/10.1186/1471-2466-14-4/fulltext.html

Reference23 articles.

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2013: Global strategy for the diagnosis, management and prevention of COPD. 2013, http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html ,

2. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008, 359 (15): 1543-1554. 10.1056/NEJMoa0805800.

3. European Medicines Agency (EMA): Bretaris Genuair (aclidinium bromide) summary of product characteristics. 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002706/WC500132732.pdf ,

4. Food and Drug Administration (FDA): Tudorza pressair (aclidinium bromide) US prescribing information. 2013, http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202450s000lbl.pdf ,

5. European Medicines Agency (EMA): Seebri Breezhaler (glycopyrronium bromide) Summary of Product Characteristics. 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdf ,

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020–2023;Lung;2024-02-06

2. Tiotropium bromide in the treatment of chronic obstructive pulmonary disease;PULMONOLOGIYA;2023-12-13

3. COPD and glycopyrronium responsiveness assessment: An appraisal;Lung India;2023

4. The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan;Journal of Clinical Medicine;2022-10-21

5. Comparative Study on the effectiveness of Glycopyrrolate/Formoterol versus Tiotropium/Formoterol in patients with Chronic Obstructive Pulmonary Disease;Contemporary Clinical Trials Communications;2022-08